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Chronic Graft Versus Host Disease (cGVHD) is a major complication of allogeneic stem-cell
transplantation (SCT). In many inﬂammatory ﬁbrotic diseases, such as Systemic Scleroderma
(SSc) and cGVHD with ﬁbrotic features, an abnormal activation of transforming growth factor
(TGFβ) and platelet-derived growth factor receptor (PDGF-R) pathways have been observed.
Tyrosin Kinase Inhibitors (TKIs), which are currently used for treatment of patients with Chronic
Myeloid Leukemia (CML), share potent antiﬁbrotic and antiinﬂammatory properties, being powerful
dual inhibitors of both PDGF-R and TGFβ pathways. Moreover accumulating in vitro data conﬁrm
that TKIs, interacting with the TCR and other signalling molecules, carry potent immunomodulatory
effects, being involved in both T-cell and B-cell response. Translation to the clinical setting revealed
that treatment with Imatinib can achieve encouraging responses in patients with autoimmune
diseases and steroid-refractory cGVHD, showing a favourable toxicity proﬁle. While the exact
mechanisms leading to such efﬁcacy are still under investigation, use of TKIs in the context of
clinical trials should be promoted, aiming to evaluate the biological changes induced in vivo by
TKIs and to assess the long term outcome of these patients. Second-generation TKIs, with more
favourable toxicity proﬁle are under evaluation in the same setting.
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1. INTRODUCTION
Chronic GVHD (cGVHD) is a late complication of allogeneic SCT, previously identiﬁed as any GVHD
manifestation occurring or lasting more than 100 days after transplantation [1]. Recently, new diagnostic
criteria for cGVHD were proposed by the NIH Consensus Conference, based on different clinical
manifestations rather than time of onset [2].
cGHVD symptoms are reminiscent of a variety of autoimmune diseases (SSc, Sj¨ ogren syndrome,
systemic lupus erythematosus, primary biliary cirrhosis, bronchiolitis obliterans, and immune cytopenias).
Pathognomic features (i.e., sufﬁcient for establishing a diagnosis) include sclerosis, lichen-planus-like
lesions, poikiloderma, esophageal webs, fasciitis, and bronchiolitis obliterans. Skin is the most common
site involved in cGVHD at the initial diagnosis in about 75% of subjects [3]. Pathology of skin lesions is
characterized by an intense mononuclear inﬂammatory inﬁltrate with destructive changes at the dermal-
epidermal junction, accompanied by irregular acanthosis, hyperkeratosis, or atrophy, progressing to dermal
ﬁbrosisandsclerosis[4]. Otherinvolvedorgansincludemouth,liver, eye,gastrointestinaltract, lung,female
genital tract, and joints [3].
Although cGVHD is associated with beneﬁcial graft versus tumor effects and with lower relapse
rates, cGVHD is still the major cause for late transplant-related mortality after allogeneic SCT. Indeed,
the profound immunosuppression, associated with cGVHD and the immunosuppressive treatment, is
responsible for severe infections and secondary malignancies in these patients. As a net effect, in patients
receiving SCT for a malignant disorder, there is around a 10% absolute survival disadvantage at 10 years
for those with cGVHD versus those without cGVHD [5, 6].
The main risk factor for cGVHD is the history of a previous acute GVHD (aGVHD) [7]. This
association is still evident after reconsidering diagnosis following the new diagnostic criteria proposed
by the NIH Consensus Conference. Other speciﬁc risk factors for cGVHD include female donor for male
recipients, older patient age, and the use of mobilized peripheral blood cells, while the use of mismatched
and unrelated donors is a common risk factor both for aGVHD and cGVHD [7].
1.1. Pathogenetic Pathways Involved in cGVHD
In allogeneic SCT host immune cells, which are responsible for recognition and rejection of nonself-
antigens, are eradicated by conditioning, thus allowing engraftment by donor cells. Host and donor
haplotypes can be differently mismatched, and this fact underlies the potential for host-directed immune
reaction in GVHD. These circumstances were summarized by Billingham in 1966 in three requisites for the
development of GVHD: (I) the graft must contain immunologically competent cells, (II) the recipient must
express tissue antigens that are not present in the transplant donor, and (III) the patient must be incapable of
mounting an effective response to eliminate the transplanted cells [8]. Subsequent work has tried to better
clarify the pathogenetic mechanisms of each of the GVHD syndromes, elucidating the contribution of the
different cell lineages of the immune system and soluble mediators.
While it is generally accepted that aGVHD is mainly dependent on donor mature cytotoxic
T lymphocytes, recognizing minor histocompatibility antigens presented by host APC, there are still
controversies about the pathogenesis of cGVHD [9, 10]. Direct evidences in humans are difﬁcult to
generalize because of the pleomorphic presentation of this syndrome; at the same time, a wide array of
cGVHD animal models have been generated,from which signiﬁcantmechanismscan be hypothesized[11–
13]. However, two important caveats must be kept in mind while interpreting the results of these models:
(I) the kinetics of clinical cGVHD in humans are slower, as they arise in patients who have already been
extensively treated with immunosuppressive agents as prophylaxis and/or therapy for acute GVHD; (II)
even if clinical cGVHD arises de novo and in the absence of active immunosuppression, it is not possible
to deﬁnitively rule out the impact of either GVHD prophylaxis and/or subclinical acute GVHD on the
subsequent development of cGVHD [14].
Notwithstanding this, three pivotal actors have clearly elucidated in the cGVHD development: T
cells, B cells, and proﬁbrotic-inﬂammatory cytokines.
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T Cells
Donor T cells are certainly necessary for both aGVHD and cGVHD [15]. T cells reactions are directly
proportional to the grade of haplotype mismatch, being incompatibility of more than 2 of 8 class HLA I and
II loci of major histocompatibility complex (MHC), invariably lethal. T-cell depletion in the haploidentical
SCT setting has been shown to circumvent the occurrence of acute and cGVHD [16]. In common
circumstances of allogeneic SCT, donor and host mismatches are limited to 7/8 or 8/8 MHC matching,
while minor histocompatibility antigens are not screened, and thus, donor and host differ for several alleles.
Similarly, many mouse models of cGVHD are generated by grafting donor bone marrow (BM) cells
intoarecipientwhichhasthesameMHChaplotypebutisfromadifferentstrain.However,thisexperimental
setting is not speciﬁc for cGVHD: only particular combinations of donor/recipient strain result in cGVHD,
while other couplings or simply swapping donor/recipient strain could lead to aGVHD; hence, the antigens
and the kind of immune response are likely to participate to the determination of the clinical phenotype as
well [11, 12].
A common theory hypothesizes that cGVHD is a chronicized immune and inﬂammatory response
driven by persistent stimulation by recipient alloantigens. As opposed to aGVHD, the pattern of response
reliesmore ontheTCD4+arm thanonCD8+andischaracterizedbyTh2cytokinesexpression.Likewisein
somechronicparasiticinfectionasschistosomiasis,thenatureofthe microbialantigensandtheirpersistence
leads to a polarized Th2 immune response,with emergence of features of chronic inﬂammation and ﬁbrosis
[17].
Alternatively, cGVHD can be considered as a melting pot of different autoimmune diseases, in
which the pathogenetichallmark is the emergenceof autoreactive(i.e., recognizingautoantigensas nonself)
clones of T and B cells [18]; breaking of tolerance is, however, invariably sustained by autoreactive CD4+
lymphocytes,which are necessaryfor maintaining and amplifying the autoimmune reaction [19]. Similarly,
in cGVHD, a dysfunction of central tolerance has been theorized, based on the evidence of thymic damage,
caused by a combination of preparatory regimens, aGVHD and older age (which are indeed risk factor
for cGVHD) [20–22]. Experimental conﬁrmation of this hypothesis was provided by a mouse model of
thymic dysfunction, in which lethally irradiated C3H/HeN (H-2k) recipients were reconstituted with T-
cell-depleted BM cells from MHC class II-deﬁcient (H2-Ab1−/−) B6 (H-2b) mice. In this model, thymic
negative selection, which relies on thymic dendritic cells (DC), is crippled, because recipient DC are
deleted by conditioning and donor DC are functionally incompetent. This leads to the emergence of donor-
and recipient-reactive CD4+ clones, which are responsible for a phenotype faithfully reproducing human
cGVHD [23].
In 1997, a new population of naturally occurring T CD4+ lymphocytes with fundamental roles in
controlling immune responses was discovered (T regulatory cells or TReg) [24]. These cells were ﬁrst
identiﬁed as bearing high levels of the membrane-bound IL-2Ra (CD25), while subsequent reﬁnement
included the expression of the transcriptional regulator FoxP3 and lack of the IL7-Ra chain (CD127) as
additional molecular markers [25, 26]. Absence or defective function of TReg has been correlated with
autoimmunity in humans, whereas their presence has been associated with tolerance [27]. TReg have
been extensively investigated as potential actors involved in GVHD, with contradictory ﬁndings: a positive
correlation between high numbers of circulating FOXP3+CD4+CD25hi TReg cells and reduced GVHD
incidence has been found in some studies [28, 29], whereas other studies showed inverse correlation
[30, 31]. Also, it remains unclear whether the blood compartment is representative of TReg content and
activity in secondary lymphoid organs and target tissues. Frequency of TReg in peripheral tissues was
evaluated in only one study, showing a reduced number of these cells in the intestinal mucosa in patients
with acute and cGVHD, compared to transplanted patients without GVHD [32].
The ability of TReg to induce antigen-speciﬁc suppression aroused a lot of interest as therapeutic
option in GVHD. In May 2008, the ﬁrst patient with steroid-refractory cGVHD with severe lung
involvement was treated with adoptive transfer of TReg cells, taken from the donor and expanded ex vivo.
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This treatment achieved not only a reduction of steroids, but also signiﬁcant improvement in the bronchial
obstruction to the level that bronchodilators could be ceased [33].
To date, however, no other reports for speciﬁc treatment of cGVHD with TReg infusions have been
published.
B Cells
B cells have been recognized for a long time as important players in the pathogenesis of cGVHD [34].
From early reports, occurrence of a variety of auto-Abs was established in cGVHD, of which many
already described in rheumatologic conditions [35]. Nevertheless, auto-Abs production does not stand
per se as a proof of a pathogenic role for B cells, but, as in similar autoimmune conditions, it could
simply represent an epiphenomenon of immune cell activation. However, at least two evidences disagree
with this latter interpretation: (I) it was shown that Y chromosome-encoded miHA elicit speciﬁc antibody
responses following sex-mismatched HSCT, and the presence of these alloantibodies closely correlates
with the development of cGVHD, while their reduction after B-cell depleting therapy is associated with
clinical response[36, 37]; (II) pathogenetic auto-Abs stimulating PDGF-R have been described in extensive
sclerodermatous cGVHD [38] (see next paragraph).
Expansion of autoreactive B cells is thought to be a process relying on the cooperation with T
autoreactivehelperwhoshare the sametarget antigen[19]; however,it hasbeenspeculatedthat in particular
conditions, activated B cells can expand and produce IgG without requiring additional antigen stimulation
[39]. In cGVHD, inadequate reconstitution of naive B cells is associated with persistence of high levels of
the B cell activating factor (BAFF) that might support antigen-independent expansion of activated CD27+
B cells [40, 41].
Moreover, B cells are essential in many functions other than Abs secretion: these include direct
antigen-presentation with priming of T lymphocytes and secretion of cytokines that modulate the intensity
and type of immune response [34]. Increased levels of TLR9 expression have been documented in B cells
fromcGVHDpatients,suggestinganimprovedability ofthesecellsto actasantigenpresentingcells(APCs)
and to sustain a chronic inﬂammatory environment [42].
Last but not least, emerging data show clinical responses from depletion of B cells with Rituximab
(RTX), further strengthening the notion of a pathogenic role for B cells in cGVHD (see next paragraph).
Proﬁbrotic-Inﬂammatory Cytokines
SSc is an autoimmune disease characterized by chronic inﬂammation and ﬁbrosis of the target organs [43].
Scleroderma-like changes in cGVHD occur in up to 13%–15.5% of patients [3, 44]. Many similarities in
the clinical picture and pathological description have been noticed between cGVHD and SSc so that a
category of mouse models of cGVHD with scleroderma-like features has been generated to gain insights in
the mechanisms of immune-mediated ﬁbrosis, largely contributing also to pathogenetic studies in SSc [11].
Most of these cGVHD models can be achieved by transplanting B10.D2 BM cells into a TBI-conditioned
BALB/crecipient(the doseofradiation canalsoaffecttheseverityofdisease).This modelis MHC matched
but differs in numerous minor HLA antigens and results in overt skin and lung ﬁbrosis [45, 46]. CD4+
T cells are certainly necessary for the disease, but several lines of evidence point to a pivotal role of
cytokines, chieﬂyT G F - β, in the development of ﬁbrotic changes [47]. McCormick et al. described the
temporal sequence of cellular changes and the molecular events occurring in this model: TGF-β-1 mRNA
upregulation in the skin and mononuclear cell inﬁltration, composed by activated monocytes/macrophages
and T lymphocytes, are seen as early as a week after BMT and precede detectable increases in collagen
mRNA and skin thickening (at day 21) [47, 48]. Administration of anti-pan-TGF-β Abs reduced cell
inﬁltrate and reversed skin and lung ﬁbrosis [47]. Effects of TGF-β, however, were not dependent on
the abrogation of immune cell inﬂux, as similar inhibition of ﬁbrosis was achieved with LAP (latency-
associated peptide), a naturally occurring regulator of TGF-β bioavailability, residing in the extracellular
matrix (ECM), without affecting cutaneous immune cell inﬁltration [49].
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Besides TGF-β, also PDGF has been considered a relevant mediator of ﬁbrosis both in scleroderma
and in cGVHD. Our group has recently demonstrated that patients with SSc are characterized by serum
stimulatory autoAbs targeting the receptor of platelet-derived growth factor (PDGF-R). Upon engagement
of PDGF-R, these Abs activate a downstream signaling cascade (Ha-Ras-ERK 1/2-ROS), composed of Ha-
Ras, extracellular-signal-regulated kinases 1 and 2 (ERK 1/2) and reactive oxygen species (ROS). High
levels of ROS, in turn, stabilize Ha-Ras, further perpetuating this loop, which ultimately leads to increased
collagen gene expression and acquisition of the myoﬁbroblast phenotype [50]. Keeping in mind these data,
we subsequently evaluated 19 patients with extensive cGVHD for the presence of stimulatory auto-Abs,
directed against the PDGF-R. Stimulatory Abs to the PDGF-R were found selectively in all patients with
cGVHD, but in none of the control group of patients without cGVHD. Higher levels were detected in
patients with generalized skin involvement and/or lung ﬁbrosis. Abs recognized native PDGF-R, induced
tyrosine phosphorylation, accumulation of ROS, and stimulated type 1 collagen gene expression through
the Ha-Ras-ERK1/2-ROS loop [38]. Primary ﬁbroblasts derived from SSc and cGVHD patients were found
to express chronically higher levels of Ha-Ras with respect to ﬁbroblasts from patients without cGVHD. In
line with this observation, it was demonstrated that lentiviral-mediated overexpression of Ha-Ras in mouse
skin ﬁbroblasts induced collagen upregulation and conversion to the myoﬁbroblast phenotype [51]. Taken
together,thesedatasuggestsaroleoftheseauto-Absinthedevelopmentofﬁbrosisandarguesforacommon
pathogenetic trait in cGVDH and SSc phenotypes.
2. RATIONAL FOR USING TKI IN cGVHD
2.1. Treatment Options for Patients with Steroid-Refractory/Dependent cGVHD Are Limited
Systemic treatment of cGVHD is usually indicated if ≥3 organs are affected or if involvement in any single
organis severeanddebilitating. Systemic treatmentis alsoconsideredfor patientswith mild overallcGVHD
severity if they present characteristics associated with poor prognosis (i.e., platelets below 100,000/mm3,
progressive onset) [52].
Data from the Fred Hutchinson Cancer Research Center on patients with cGVHD show that there
has not been any signiﬁcant, meaningful improvement in overall or relapse-free survival from 1980 to
2006 [5]. Up to date steroids (with or without a Calcineurin Inhibitor) are the mainstay for patients with
extensive cGVHD, but many patients have a suboptimal response to steroids and are unable to discontinue
steroids even after months or years of therapy [5, 53, 54]. Steroid tapering, according to common protocols,
is usually slow, exposing patients to substantial side effects. Moreover, in pediatric patients, systemic
steroid therapy can be deleterious on a growing child [55]. Finally steroids require monitoring for steroid-
induced osteoporosis and diabetes mellitus. Therefore, addition of an effective steroid-sparing agent for
these patients is of crucial importance for long-term outcome and for the quality of life (QOL) [56].
Prognosis remains poor for those who do not show any response to ﬁrst-line treatment (steroid resistant)
and those who, although responding, are not able to taper steroids because of ﬂares occurrence (steroid-
dependent disease). These patients have been considered to have steroid-refractory disease, for which
generally accepted criteria are (1) progression on prednisone at 1mg/kg/day for 2 weeks, (2) stable disease
on 0.5mg/kg/day of prednisone for 4–8 weeks, and (3) inability to taper prednisone below 0.5mg/kg/day
[57, 58].
While primary treatment of cGVHD is based on controlled trials, in contrast, evidences for the
secondary management of steroid refractory cGVHD are limited almost to phase II trials or retrospective
studies. Therefore, it is not surprising that there is no standard approach for steroid refractory cGVHD and
these patients should rather be entered on treatment protocols [52, 57].
A number of Phase II trials of secondary agents have been published, reporting encouraging
response rates. The most promising results have been achieved with RTX [59–68], ECP (Extracorporeal
Photopheresis) [69, 70], and Pentostatin [71]. However, most trials contain relatively few patients with
heterogeneous organ involvement and advanced phases of organ manifestations [72–79]( Table 1).
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TABLE 1: Response rate and outcome reported in the main clinical trials for patients with refractory cGVHD.
2nd line treatment
Response rate
(patients number: N)
Organ-speciﬁc
response rate
Main side effects References
Mycophenolate
mofetil
46–75%
N = 21–26
Skin 53% (n = 15)
Mouth 67% (n = 15)
Liver 54% (n = 13)
Gastrointestinal disturbances
(diarrhea, nausea, and vomiting)
[72–74]
High-dose
cortico-steroids
48% major responses
N = 56
Not Reported
Infections, diabetes
decompensation, and
psychological effects
(psychosis and insomnia)
[75]
Extracorporeal
photopheresis
61%
N = 71
Skin 40% (n = 48+17)
Sclerotic skin 67% (n = 21)
Mouth 77% (n = 7)
Eye 64% (n = 4)
Lung 54% (n = 6)
Anemia, requirement for central
IV access
[69, 70]
Pentostatin
53% major responses
+2% minor
responses N = 58
Lichenoid skin 69% (n = 39)
Sclerotic skin, fascial, and
mouth 52%–57% (n = 39)
Nausea, vomiting, infection,
renal dysfunction, rash, and
headache
[71]
Tacrolimus
46%
N = 26
Not Reported
Renal dysfunction, thrombotic
microangiopathy,neurotoxicity,
and hypertension
[77]
Rituximab
Meta-analysis of
7 studies: OR 66%
(CI: 57–74%)
N = 111
Skin 60% (n = 67)
Oral mucosa 36% (n = 46)
Liver 29% (n = 34)
Lung 30% (n = 14)
Infusion reactions, infections,
and hepatitis reactivation
[58–68]
Sirolimus
63–94%
N = 16–35
Skin 65% (n = 29)
Mouth 75% (n = 8)
Liver 33% (n = 6)
Eye 64% (n = 11)
GI 67% (n = 6)
Hypertriglyceridemia,renal
insufﬁciency, cytopenias,
infections
[77, 78]
In many studies on second-line treatment of cGVHD, drugs like mycophenolate, sirolimus, or ECP
werecombinedwithcontinuoussteroidadministration[70,73,74,77–79].Thus,thecontributionofsteroids
to the reported response rates in these studies remains uncertain. Furthermore, steroid sparing should be an
important goal of salvage therapy of cGVHD. Because no predictors of response are yet available either
for single immunosuppressiveagents or combination therapies, most patients receive empirical treatment in
daily clinical practice and changes of therapeutic components in case of lack of response are performed at
the individual clinician’s discretion [52].
2.2. TKIs Can Be Safely Administered after Allogeneic SCT
TKIs are a class of drugs comprising small molecule inhibitors of oncogenic tyrosine kinases (TK), which
have recently been developed for treating several malignancies. Among these drugs, Imatinib Mesylate
showeda speciﬁcinhibitory effect on CML cells andBCR-ABL-transformed cells both in culture and when
grown as tumors in mice. Since 1986, phase II clinical trials showed that Imatinib was effective in treating
chronic phase CML, and up to date this drug is the most largely used in CML with ≥100,000 patients
treated. Imatinib not only inhibits BCR-ABL but also is almost equally potent against PDGFRα and c-KIT
receptor tyrosine kinases [80]. c-KIT receptor TK is implicated through activating mutations in GIST [81];
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indeed,Imatinib andotherTKIsareeffectivealsoinpatientswith GIST[82]. Imatinib hasalsobeentestedin
the treatment of other malignanthematopoietic diseases,includinghypereosinophilicsyndromeandchronic
eosinophilic leukemia,which also expressan activatedform of PDGFRα [83]. Finally,somereports suggest
a limited efﬁcacy of these drugs in patients with systemic mastocytosis with 816 KIT mutations, causing
constitutive activation of TK activity of the molecule [84].
More recently, this drug has been also tested in patients with autoimmune diseases and cGVHD (see
later).
The acute and chronic safety proﬁle of TKIs has been extensively evaluated in CML patients, and
the most studied drug is Imatinib [85]. A common observation is that in patients with early disease, the
hematologicaltoxicity ismild, while relevantmyelosuppressionhasbeenreportedin patientswith advanced
disease [86]. Common extrahematological toxicities that have been reported with Imatinib include nausea,
vomiting, diarrhea, fatigue, muscle aches, ﬂuid retention, and skin rash [87]. The concern that Imatinib
may lead to more severe toxicities such as cardiac heart failure was ﬁrst reported by Kerkela et al. [88]
Subsequently, the issue of Imatinib-related cardiac toxicity in the non-SCT setting has been addressed
by several investigators [89–91]. In each of these reports, cardiac failure and left ventricular dysfunction,
which was possibly or probably related to Imatinib therapy, were either not identiﬁed [89] or were found
to occur rarely (0.04%/year) as in the International Randomized Study of Interferon and ST1571 trial [90].
In conclusion, since the original report, no further evidence to support an increased risk of cardiac toxicity
has emerged with Imatinib [92]. Nilotinib and Dasatinib have a different toxicity proﬁle that has been
extensively studied in CML patients [93, 94], but there are still few data regarding the safety of these
drugs outside the setting of CML, especially in patients undergoing allogeneic SCT. Some experiences
with Imatinib suggest that TKIs use in the peritransplant period had no effect on either TRM or cardiac
toxicity, while the potential myelosuppressive effects of Imatinib could be relevant, with conventional
doses. Anderlini et al. [95] treated 15 patients who received allogeneic SCT for Ph+ leukemia and doses
above200mg/day of Imatinib were frequently associatedwith grade 3-4 cytopenias.In a more recentreport
focusing the tolerability of Imatinib during the ﬁrst 90 days after myeloablative allogeneic SCT, Carpenter
et al. did not found severe toxicity. When emesis and nausea were not associated with GVHD or infection,
symptomsweregenerallymanageablebydivideddosingorbyantiemeticadministration.AlthoughImatinib
may have contributedto transaminaseelevations,other temporal associationswere noted,includingGVHD,
infection, and triazole antifungal medication. The same author found that administration of Imatinib do not
affect calcineurin inhibitor (Cyclosporin and Tacrolimus) levels [96]. Recent data also suggest the safety of
second-generation TKIs, in Ph+ ALL and CML patients who have undergone prior allogeneic SCT.
Dasatinib is a second-generation TKI that inhibits a wider range of tyrosine kinases than Imatinib,
includingBcr-Abl andSRC family kinases,andis 300-fold more potent thanImatinib [97]. A phaseII study
of Dasatinib at 140mg in patients with Imatinib-resistant or intolerant Ph—ALL, including 15 patients who
previouslyreceivedallogeneicSCT,wasreported[98]. However,variousadverseeventshavebeenobserved
with the use of Dasatinib, including myelosuppression,bleeding-relatedevents,and ﬂuid retention. Caution
should be paid to the possibility of adverse effects of Dasatinib, especially infectious complications and
gastrointestinal bleeding [99].
Nilotinib was developed as a more potent and more selective inhibitor of the Bcr-Abl protein,
compared to Imatinib. In contrast, the mean IC50 for the inhibition of the phosphorylation of PDGFRα/β
(in A31 cells) was similar for the 2 drugs (71 ± 7nM and 74 ± 11nM) and for the inhibition of c-KIT
(GIST882 cells) was higher with Nilotinib (200 ± 13nM) than with Imatinib (96 ± 12nM) [100].
Myelosuppression was reported more frequently in patients with advanced phase CML, but severe
clinical consequences such as febrile neutropenia, sepsis, pneumonia, and bleeding associated with
thrombocytopenia occurred infrequently. Elevations in serum lipase was reported in a 10% of patients;
these were generally transient and easily managed with brief treatment interruptions. Low grade increases
in bilirubin and hepatic transaminases were frequently observed; however, grade 3/4 events occurred very
rarely. Nilotinib has demonstrated a modest, dose-related potential for QT interval prolongation, but there
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were no episodes of torsades de pointes observed in patients treated to date. The rates for pleural or
pericardial effusionsandedemawerelow bothin patientswith early phaseCML andpatientswith advanced
phase CML [93, 94]. Preliminary data suggest that Nilotinib is well tolerated also in patients who have
received an allogenic transplantation [101].
Bosutinib (SKI-606) is an orally active Src and Abl kinase inhibitor presently in Phase III trials for
treatment of chronic myelogenous leukaemia (CML) and in Phase II trials for treatment of breast cancer.
Recent studies indicate that Bosutinib is active against a broader spectrum of kinases, and these additional
inhibitory activities have interesting possibilities for further clinical development [102]. However, clinical
data concerning the potential use of this drug in patients with cGVHD are lacking.
2.3. TKI Have Immunomodulatory Properties by Inﬂuencing Different Cell Populations
TKIs can interfere both with the innate immunity and with the adaptive immune response, interacting
with different cell populations: T-cells, B-cells, dendritic cells, mast cells, and macrophages (Figure 1).
As TK play a pivotal role in T-cell receptor (TCR) and B-cell receptor (BCR) signal transduction, one can
expectthat these drugs may also interfere with these processes.Severalexperimentsindeed demonstratethe
physiological role of TK in both T-cell and B-cell receptor signal transduction. T-cells lacking functional
Abl show decreased interleukin-2 production and cell proliferation in response to the stimulation of T-
cell Receptor (TCR) [103]. Moreover Abl phosphorylates the B-cell receptor (BCR), coreceptor CD19,
suggesting a role for Abl also in regulation of B-cell proliferation [104]. According to these observations,
Abl knocked-outmice display several defects both in T- and in B-cell development[105]. Finally, the effect
on c-KIT may also contribute to an immunomodulating activity of TKIs [106].
Clinical retrospective observations in patients with CML and concomitant autoimmune pathology
demonstrated an improvement of clinical autoimmune symptoms during Imatinib treatment [107, 108]. Our
preliminary data suggest that immunoglobulins from cGVHD patients, responding to Imatinib treatment,
have reduced stimulating activity on quiescent ﬁbroblasts, compared to baseline stimulatory activity
(accordingly to the presenceof agonistic anti-PDGF-R antibodies) [109]. Furthermore in vitro data indicate
that Imatinib potently inhibits diverse cellular responses and interacts with diverse cell subsets, involved
both in innate and in the adaptive immunity [110].
T-Cells
Imatinib inhibits DNA synthesisin human T cells stimulated with allogeneic mature dendritic cells but does
not induce apoptosis within the concentration range found in CML patients treated with this drug. These
effects are dosedependent and have been conﬁrmed in a murine model of delayed-type hypersensitivity
[111, 112]. The consequent reduction of T-cell proliferation may have synergistic effects with other drugs
affecting the same pathways,such as some calcineurin inhibitors, and this may be particularly important for
TCR-mediated IL-2 production [113].
The interactions between TKIs and T-cells have been recently reviewed by Seggewiss et al. [114];
experimental data indicate that Imatinib, Dasatinib, and Nilotinib exert a direct inhibition of c-Abl and
can modulate the related TK in the T-cell signaling pathway. These speciﬁc mechanisms include reduced
phosphorylation of ZAP-70 and other kinases (LAT, LCK, and ERK1/2) and reduced levels of activated
NFκB. TKIs binds the SRC-family kinase LCK and inhibits the LCK signaling pathway at therapeutically
concentrations comparable to that observed in humans receiving TKIs [111, 112, 115]. LCK is a major
playerinproximal T-cellsignaling;TCR-mediatedsignaltransductionleadsto activationoftheSRC family,
TKs LCK and FYN, which are associated with the coreceptors CD4 and CD8 [116]. Activated LCK and/or
FYN, in turn, phosphorylate the immunoreceptor tyrosine-based activation motifs (ITAMs), located within
the CD3 and z chains of the TCR/CD3 complex itself. The phosphorylated ITAMs serve as a docking site
for ZAP70, which is also a substrate for LCK. ZAP70, in turn, phosphorylates the Tcell-speciﬁc adapters
LAT and SLP-76, which generate the secondary messenger effectors of T-cell activation and proliferation.
(Figure 2).
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FIGURE 1: TKIs interact with several immune cells∗ by direct or indirect link to the indicated molecules.
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FIGURE 2: (A) After linking between TCR and MHC-peptide and after coreceptor CD4 engagement, LCK
and Fyn kinases are activated. LCK and Fyn in turn phosphorylate TCR complex and c-ABL. (B) ZAP-
70 links phosphorylated TCR and is phosphorylated itself by c-abl. So ZAP-70 can phosphorylate other
downstream kinases (SLP-76, LAT) to permit T-cell activation and proliferation. P: phosphate; MHC: major
histocompatibility complex; T: T-lymphocyte.
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Also, Dasatinib inhibits TCR-mediated signal transduction, cellular proliferation, cytokine produc-
tion, and in vivo T-cell responses,without inducing apoptosis.Combination with other immune-suppressive
agents such as cyclosporine A or rapamycin leads to a much more potent inhibition of T-cell activation,
suggesting that targeted inhibition of LCK could be a useful adjunct for enhanced immunomodulation
[117]. Because the ability of Dasatinib to inhibit LCK is 1,000-fold higher compared with Imatinib and it
also inhibits FYN [118], the immunosuppressiveeffects of this SRC kinase inhibitor on T cells are likely to
be much more profound than those of Imatinib or Nilotinib.
Different T-cell subsets exhibit different thresholds for inhibition, with CD4+ T cells being
marginally more sensitive than CD8+ T cells and naive T cells being more sensitive than memory T-cell
subsets.This latter observationmight reﬂectdifferential expressionlevelsofLCK,whichplaysanimportant
role in proximal signal transduction [119].
T-Regulatory Cells
As mentioned before, up to date, the role of regulatory cell subsets in cGVHD pathogenesis is still
controversial, and, similarly, the role of TKIs in the regulation of this subset is still incompletely
characterized.Some in vitro studiesshowthat TRegimmunosuppressivefunction and FoxP3expressionare
impaired by therapeutic concentrationsof Imatinib, while TRegproliferation is not signiﬁcantlymodiﬁed.It
has been demonstrated that Imatinib signiﬁcantly reduces the activation of the transcription factors STAT3
and STAT5 and inhibits phosphorylation of ZAP70 and LAT in TReg [120]. Imatinib treatment in mice
decreased TReg frequency and impaired their immunosuppressive function in vivo.
Although the different effects of TKIs at therapeutical concentrations on these pathways deserve
further studies, these preliminary observations make TKIs potential candidates as immunomodulatory
agents for targeting TReg in cancer immunotherapy or autoimmune diseases. However, the hypothetical
mechanismswhichcould be involved in a possible inhibition of autoreactiveor alloreactiveclonesby TReg,
during the administration of TKIs are unclear.
B Cells and Other Immune Populations
Imatinib blocks c-Abl kinase activity at submicromolar concentrations [121, 122]; consequently, the
inhibition of the BCR signalling reduces the B cell proliferation and IgM production in vivo; this
can translate in a possible inhibition of the autoreactive B cell responses. Retrospective data show
indeed that a relevant proportion of CML patients, treated for a long time with Imatinib, develop
hypogammaglobulinemia [123, 124].
DC and donor T-cell interactions, with respect to GVHD in SCT have been recently focused. Src
kinases play a central role in DC activation [125, 126], and some studies suggest that Imatinib also
negatively affects DC number and function. High concentrations of Imatinib inhibit the development
of human CD34+ progenitors and monocytes to DC and hamper the induction of primary Cytotoxic
T Lymphocytes because of low-level expression of costimulatory molecules [127, 128]. However,
contradictory results have been reported, as DC treated with Imatinib can also exhibit enhanced APC
function and could break the tumor-induced tolerance [129, 130]. Recent reports have described a new
type of immune cell in mice, the “interferon-producing killer dendritic cell” (IKDC). Experimental results
indicated that these cells mediate antitumor effects in vivo, both by killing target cells and by subsequently
presenting antigens from target cells. These cells might provide a pivotal link between innate and adaptive
T-cell immunity [131, 132]. Interestingly, stimulation of these IKDC subset with imatinib and IL-2 led to
inﬁltration of tumor masses by these cells in a murine model [133]. Whether immune surveillance of tumors
is a normal function of IKDC in mice or was induced by Imatinib remains unclear. Furthermore, it is not
yet known how Imatinib exerts this effect in mice and whether such properties are transferable to humans.
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2.4. TKI Have a Potent In Vitro and In Vivo Anti-Inﬂammatory and Antiﬁbrotic Activity
Several reports suggest that efﬁcacy of TKI in autoimmune diseases does not rely solely on modulation
of adaptive immunity but also on interference with mechanisms of innate immunity and inﬂammation.
Paniagua et al. recently tested Imatinib successfully in an animal model for arthritis [110]. Experimental
data suggested that T cells are inﬂuenced by Imatinib only at supratherapeutical levels, while the key
effects in this model are mediated by other cell lineages which are more involved in innate immunity and
inﬂammation.
Imatinib couldinhibit activationofsynovialmacrophagesand TNF-α productionin responseto LPS,
an effect that could be mediated by c-fms; Imatinib prevented mast cell production of proinﬂammatory
cytokines, probably through blockade of c-kit signaling; ﬁnally, in synovial ﬁbroblasts from rheumatoid
arthritis patients, Imatinib halted proliferation through PDGFRβ [110].
In another study, Imatinib was able to prevent and reverse the development of autoimmune diabetes
in the NOD mouse [134]. In the same model, Sunitinib, a multitarget TKI which lacks speciﬁcity for c-
Abl, was equally effective, demonstrating that c-Abl was dispensable for blocking the disease. Additional
experiments with another TKI, PLX647 (targeting c-Kit and c-Fms), or an anti-c-Kit mAb showed only
marginal efﬁcacy, whereas a soluble form of anti-PDGF-R Ig rapidly reversed diabetes, suggesting that
inhibition of PDGF-R is critical to reverse diabetes, suggesting the crucial role of inﬂa m m a t i o ni nt h i s
model [135].
The potential of Imatinib and other TKIs as antiﬁbrotic therapeutic agents was initially supported
by evidence of efﬁcacy in the mouse model of bleomycin-induced dermal ﬁbrosis. In this model, Imatinib
potently reduced the dermal thickness, the number of myoﬁbroblasts, and the collagen content of the skin
in a dose-dependent manner and at well-tolerated doses [136, 137]. Similar results were obtained in the
same experimental context with Dasatinib and Nilotinib [138]. In this study, the dose range that yields
therapeutically relevant concentrations was also identiﬁed, which can also be achievedin humans,being for
Dasatinib from 3mg/kg to 10mg/kg and for Nilotinib from 12.5mg/kg to 37.5mg/kg BID [94, 138–141].
A potent antiﬁbrotic effect of Imatinib was also observed in animal models of pulmonary, renal,
cardiac, and liver ﬁbrosis [142–145].
In the clinicalsetting, Imatinib demonstratedconsiderableefﬁcacyin variousﬁbroticdisorders[146].
Kay and High [147] reported of two patients with gadolinium-induced nephrogenic systemic ﬁbrosis, who
were treated with Imatinib with remarkable improvement and, notably, worsened after cessation of this
therapy.
As mentioned later in this paper, Imatinib appears to be highly effective in patients with refractory
sclerotic cGVHD. Moreover, several case reports and early phase clinical trials suggested clinical beneﬁt
of Imatinib in patients with refractory SSc and mixed connective tissue disease, including progressive skin
ﬁbrosis and pulmonary ﬁbrosis [146]. Recently, Spiera et al. [148] published a 1-year open-label clinical
trial assessing the safety and efﬁcacy of Imatinib 400mg/d in 30 patients with diffuse cutaneous SSc.
Twenty-four patients completed 12 months of therapy; after 12 months of treatment, Imatinib improved
skin ﬁbrosis, and blinded dermatopathological analysis conﬁrmed a signiﬁcant decrease in skin thickness
and improvement in skin morphology. Lung disease remained stable in patients with interstitial lung
disease. Notwithstanding these positive results, a large double-blind, placebo-controlled, randomized trial
of Imatinib for idiopathic pulmonary ﬁbrosis in 119 patients did not demonstrate any efﬁcacy for this drug
[149].
Preclinical data underscore the peculiarity of Imatinib and other TKIs of exerting an antiﬁbrotic
effect that is independentofimmunomodulatoryand anti-inﬂammatory activity. In an elegantin vitro model
[137], Distler demonstrated that increasing concentrations of Imatinib prevented upregulation of the major
extracellular matrix (ECM) proteins COL1A1, COL1A2, and ﬁbronectin 1 in both PDGF-β-a n dT G F - β-
stimulated dermal ﬁbroblasts, at the mRNA level as well as the protein level. While the effect on PDGF-
stimulated ﬁbroblasts seems to be dependent on inhibition of PDGF-R, blockade of TGF-β ﬁbrogenesis is
hardly explained by inhibition of TGF-β receptors, which are serine-threonine kinases [150]. Nonetheless
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c-Abl, the primary target of Imatinib, turned out to be an important noncanonical mediator of TGF-β-
inducedﬁbrosis,whichotherwiseis mediatedbythe classicalSmadpathway[151, 152]. Daniels et al. [142]
ﬁrst demonstrated that ﬁbroblasts respond to TGF-β by stimulating c-Abl kinase activity independently of
Smad2/3 phosphorylation or PDGF-R activation. Moreover, c-Abl was implicated in TGF-β-induced ECM
gene expression, morphologic transformation, and cell proliferation [153, 154]. The signaling pathways by
which c-Abl mediates such relevant effects on ﬁbrogenesis have been later clariﬁed: Bhattacharyya et al.
[154]showedthat theinductionofearlygrowthresponseprotein 1(Egr-1)byTGF-β isdependentonc-Abl;
moreover,c-Abl isinvolvedinthe phosphorylation/activationofSmad1,whichresultsin theupregulationof
CCN2 (connectivetissue growth factor) [155, 156]; c-Abl activatesprotein kinaseC (PKC)-δ, which in turn
decreasesbinding afﬁnity of the antiﬁbrotic transcription factor Fli1 to the type I collagen promoter, thereby
promoting ﬁbrosis [157]; ﬁnally, c-Abl was implicated in the reduction of the antiﬁbrotic microRNA miR-
29 in SSc ﬁbroblasts [158]. Notably, all these pathways were shown to be reversible upon Imatinib addition
(Figure 3).
3. CLINICAL EXPERIENCES WITH TKIs IN cGVHD
Retrospectivedata suggestthat TKIs administration before and after allogeneic SCT may impact on GVHD
development. Some Authors observed a greater incidence of acute GVHD (grade 3-4) and a trend toward
less cGVHD in allotransplanted patients, receiving Imatinib for treating relapse of CML [92]. On the
contrary, lower incidences of cGVHD in patients who received Imatinib therapy earlier has been described
[112, 159–161].
The ﬁrst indications supporting a possible role of TKI in patients with cGVHD came from anecdotal
case reports. In 2006, a case of a 33-year-old female was reported, who received allogeneic SCT for CML,
developing a steroid-refractory cGVHD, with severe lung involvement, characterized by progressively
worsening pulmonary symptoms and severe airway obstruction. As she developed hematological relapse,
and donor lymphocyte infusion was contraindicated for the concomitant severe cGVHD, she was treated
with Imatinib. Surprisingly, her pulmonary symptoms rapidly improved during the ﬁrst 2 months of
treatment, with gradual elimination of her need for oxygen and considerable improvement in exercise
tolerance[162].In2008,Magroetal.reportedabouttwopatientswhodevelopedrefractorysclerodermatous
cGVHD following allo-SCT and received Imatinib at the dose of 400mg/day; in both patients, the
scleroderma symptoms disappeared within 3 months of initiation of the treatment [163].
Basing on our biological ﬁndings, demonstrating the presence of pathogenetic anti-PDGF-R
antibodies in patients with cGVHD [38], and on the above-citedpreliminary anecdotalreports, we designed
a phase I-II study with the primary end point to assess the safety of escalating doses of Imatinib in patients
with ﬁbrotic steroid-refractory cGVHD [164]. Imatinib administration was planned for a minimum of
6 months, starting at the initial dose of 100mg/day. After 1 month, in the absence of severe toxicity
or intolerance, the dose was increased to 200mg/day until the end of the 3rd month; afterwards, if no
responsehad occurred, and in the absenceof severe toxicity or intolerance, patients were allowed to receive
400mg/day.
This ﬁrst prospective study included nineteen both adult and pediatric patients, affected by steroid-
refractory cGvHD, with ﬁbrotic features. The ﬁrst-line treatment for cGVHD before Imatinib consisted of
steroids,whilethesecondlineincludedamiscellaneaincludingRTX,ECP,andMycophenolate.All patients
had a long history of cGVHD (median duration: 37 months) with multiorgan involvement, including skin
(17 had scleroderma skin features), lung (11), and sicca syndrome (15 patients), while 8 had other visceral
involvement.
Consideringthe kindofpathologicaldamagein manypatientswith ﬁbrotic cGVHD,receivinga drug
presumably slower than steroids (in terms of mechanism of action), the response has been evaluated in two
steps (3 and 6 months) in order to observe a possible late clinical improvement in the organs involved by
the ﬁbrotic process.
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FIGURE 3: Antiﬁbrotic effect of TKI: the original target of Imatinib, c-Abl, is involved in several molecular
pathways leading to ﬁbrogenesis. Interference of TKI with other molecules involved in ﬁbrotic pathways
(PDGFR and Src kinases) are not illustrated due to required simpliﬁcation.
Indeed, even though most patients continued Imatinib at the lower dose, the responses signiﬁcantly
improved after 6 months of treatment, with 7 CR and 8 PR (79% overall response rate), suggesting that in
this setting an early discontinuation of the treatment could be detrimental. It is notable that the response to
Imatinib allowed in 10pts to stop or to signiﬁcantly taper the steroid therapy. The recently updatedoutcome
of these patients suggests a long-term beneﬁti nt e r m so fO S[ 109]( Figure 4).
A similar study by Magro et al. retrospectively conﬁrmed the activity of Imatinib in 14 patients
with heavily pretreated refractory ﬁbrotic cGVHD. Imatinib was started at a median of 44 months after
transplantation and was administered for a median of 6 months from time of initiation. With a median
followup of 12 months from time of initiation of Imatinib, 29% of patients had to stop Imatinib because
of drug intolerance. Overall, 7 patients responded to Imatinib with 4 patients, improving the Rodnan skin
score more than or equal to 90%. Also, in this series, Imatinib therapy allowed for a signiﬁcant reduction
of corticosteroid dosage [165].
Stadler et al. [166] treated with Imatinib 9 patients with refractory cGVHD of the lung. All patients
had skin, mucosal, visceral, and/or fasciitic manifestations in addition to pulmonary cGVHD; the median
duration of pulmonary cGVHD was 6 months. All patients had already received extensive combination
therapies with steroids, calcineurin inhibitors, mycophenolate, and/or ECP. After a median duration of 4
months of treatment, pulmonary function recovered only in 1 patient from severe to moderate, and only 2
patients were able to reduce steroid dosage, whereas 5 patients showed no change, and 2 patients died due
to progression of pulmonary GVHD and/or the underlying malignancy.However, it should be observedthat
6 of the 9 were given Imatinib for only 1 to 4 months; our experience was more encouraging, as 6 of our
11 patients markedly improved their lung function score, and 2 of them were able to discontinue steroid
therapy.
In 2008, we started a second multicenter study to evaluate the safety and the activity of low-dose
Imatinib in a larger population of patients with steroid-refractory cGVHD, by using the more stringent
response criteria suggested by NIH Consensus Conference for cGVHD [2]. The enrollment has been
recently closed, and the interim analysis in the ﬁrst 24 patients conﬁrms that Imatinib is safe and well
tolerated in this setting although the response rate seems to be slightly inferior (48% at 6 months and 61%
at one year) when compared to the ﬁr s tp i l o te x p e r i e n c e[ 109].
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FIGURE 4: Updated OS in 19 patients receiving Imatinib for steroid-refractory cGVHD (Olivieri et al. [109]).
Some possible reasons could be responsible for this discrepancy: ﬁrst, in this second trial, the
response criteria are more stringent (according to those proposed by the NIH Consensus Conference on
cGVH); secondly, the average age of the patients enrolled in the second trial was signiﬁcantly superior
(48 years) to the other ones (in the ﬁrst study, the median age was 29 years, and we observed the best
responses in young and pediatric patients). Finally, a different cGVHD pattern was present in the second
series, with many patients with both lung involvementand other visceral involvement, and less patients with
SSc features or sicca syndrome.
Pooling the data of these two cohorts, 44 patients with cGVHD, refractory to two or more
lines of therapy including steroids, have been consecutively treated with Imatinib, by using the same
inclusion/exclusion criteria; 29 were male and 15 female, with median age 42 years (range 10–67). The
median duration of cGVHD was 23 (range 6–148) months, and all patients received ≥2 lines of therapy,
(including 28 previouslytreated with ECPand16 with RTX).ThemaincGVHDtargets were representedby
lung in 30 patients (Bronchiolitis Obliterans or Pneumonia/ﬁbrosis)andskinin 34(generalizedscleroderma
in 21 and localized in 13); 17 patients had Sicca syndrome, 19 other visceral manifestations, and one severe
eosinophilic fasciitis; the organ localizations were not mutually exclusive with most patients showing a
multiorgan involvement. Overall, the treatment was well tolerated, and we did not observe toxic deaths;
the hematological toxicity was mild, with only one patient developing a grade 3 anemia, while the main
grade 3-4 extrahematological adverse events were infections or ﬂuid retention. The median duration of
treatmentwas16months(range6–41).Overall,theresponserate(excludingtheminorresponses),evaluated
accordingto theNIH criteria was62%at6monthsand58%at12monthsafterthestartoftreatment.Among
30 evaluable patients, 43% of them was able to stop steroids. The best responses have been achieved in
patients with skin and gastrointestinal involvement; some measurable degree of lung functional score has
been observed in 54% of patients, but only 29% of them achieved at least PR; 51% of patients achieved a
measurable improvement of the PS score.
With a median followup of 26 months (8–41), 34 patients are alive and 10 died; 13 patients (29%)
show continuous response without any further treatment.
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FIGURE 5: Cumulative incidence of treatment failure in 44 consecutive patients, receiving Imatinib for
steroid-refractory cGVHD (Olivieri et al. [109]).
The cumulative incidence of treatment failure is 26% at 3 years, conﬁrming the preliminary data
of our ﬁrst study (Figure 5). Younger patients showed a trend for better OS although the difference is not
statistically signiﬁcant; no differences in OS according to the presence/absence of Skin involvement or the
history of previous RTX administration have been observed [109]. Finally, the OS seems not to be different
accordingto theachievementof amajor responseafter 6 monthsofImatinib (A. Olivieri, unpublisheddata).
Preliminary results of the functional test performed in IgG samples from cGVHD patients at baseline
conﬁrm the presence of anti-PDGF-R Abs with high ROS stimulating activity (A. Olivieri, unpublished
data). Although preliminary, these data also suggest a relationship with the clinical response, with a
reduction of ROS output, after the challenge of murine ﬁbroblast with IgG from responding patients [109].
4. PERSPECTIVES AND CONCLUSIONS
The biological background and the preliminary clinical data with Imatinib strongly encourage the use of
second-generation TKIs in patients with refractory cGVHD. Indeed, the options for patients with steroid-
refractory or steroid-dependent cGVHD are limited, including RTX [59–68], Pentostatin [71], and ECP
[69, 70], but only this latter approach has been validated in a randomized trial; however, this study did
not demonstrate any advantage both in OS and in the response rate, outside the improvement of the skin
score and the signiﬁcant steroid sparing [70]. While Pentostatin use in these patients may be associated
with several side effects, RTX seems more manageable, and it is not trivial to hypothesize in the future a
possible association of this drug with TKIs in these patients, considering the possible synergistic effect on
the immune system and their favourable safety proﬁle.
Like Imatinib, Nilotinib is a TKI with better tolerability proﬁle [94, 167], suggesting a better
compliance, especially in frail patients such as those with steroid-refractory cGVHD. In vitro models
suggest that the PDGF-R inhibitory effect of Nilotinib is at least not inferior than Imatinib and that serum
levels, obtained with an oral dose of 400mg/die of Imatinib, can achieve an inhibitory effect on ﬁbroblasts
activitycomparableto thatobtainedwith 800mg/dieofNilotinib [138].Inourpreviousexperience,patients’
frailty and their reduced haematological tolerance heavily limited the daily dose of Imatinib, which was, in
more than 80% of cases, only 100mg/die (only one quarter of whole dosage). Therefore, it is reasonable to
hypothesize that the better tolerability proﬁle of Nilotinib will allow to treat these cGVHD patients, with a
signiﬁcantly higher dosage; as a consequence,this could allow to achieve a tissue concentration of the drug
able to obtain an intracellular anti-PDGFR-effect approximately 4–8 times more potent than that observed
with Imatinib administered at 100mg/die.
1922TheScientiﬁcWorldJOURNAL (2011) 11, 1908–1931
On the basis of this background, we are starting a phase I-II study aimed to evaluate the safety and
activity of Nilotinib in patients with steroid-refractory or steroid-dependent cGVHD. A similar approach
with Nilotinib has been recently proposed by some EBMT Centers (personal communication).
Other clinical trials with TKIs for patients with cGVHD are ongoing. A US randomized trial
(http://Clinicaltrials.gov/ identiﬁer: NCT01309997), in cGVHD patients with skin ﬁbrotic involvement,
will evaluate the response rate at 3 and 6 months after Imatinib treatment, compared to RTX, according
to the NIH responsecriteria. Secondaryoutcome measuresare proportion of patients achievingat least 50%
reduction in the daily corticosteroid dose and cumulative incidence of treatment failure.
In conclusion, cGVHD still represents a major challenge for transplanters. Response is often
suboptimal, and the consequences of prolonged immune-deﬁciency expose the patients to infectious
complications and secondary malignancies. Indeed, cGVHD is still the leading cause of late nonrelapse
mortality in the survivors [56], and the quality of life is strongly compromised also in the responding
patients with cGVHD [168]. We have recently shown that patients with scleroderma-like cGVHD have
agonistic Abs activating PDGF-R and the biological activity of these autoAbs suggests a pathogenetic role
in the development of ﬁbrotic lesions of cGVHD and SSc. These ﬁndings argue for a common pathogenic
trait in cGVDH and SSc and suggest an alternative therapeutic approachwith TKIs as potent dual inhibitors
ofTGF-β andPDGF-Rpathways.Moreover,datafrom animalmodelsandfrom humanssuggestaclinically
relevant immunomodulatory activity of TKIs.
The combination of these two properties, together with the acceptable toxicity proﬁle of TKIs, also
in the long-term treatment, make them real candidates for the treatment of patients with cGVHD, not only
after failure of steroids, but rather to spare the steroid dosage in responding patients, and probably as a
component of combined treatments for patients with cGVHD; TKIs can be safely administered in patients
receiving Cyclosporin and have been also administered without major problems also in patients under ECP
(own unpublished data). Finally, the combination of TKIs with RTX should be explored, considering the
favourable safety proﬁle and the potential synergy of these drugs.
Of course, TKIs are unlikely to be the single magic bullet for cGVHD, but the data coming from
a particularly difﬁcult setting, such as steroid refractory cGVHD patients, indicate that Imatinib, when
used at low doses, is safe and effective. However, the long-term toxicity and the possibility of late-onset
effects, correlated to the possible immunosuppressive action of this drug should be carefully evaluated in
this particular setting [89]. New TKIs, with better tolerability proﬁle and with more potent antiﬁbrotic
and/or immunomodulatory effects, could achieve not only a better responserate, but also could improve the
complianceand the duration of treatment in respondingpatients, with a consequentimpact on the long-term
outcome of the transplantation procedure.
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